Lung Cancer

Relative risk for venous thromboembolism appeared high among patients with COVID-19 and cancer who received specific cancer treatments, according to study results published in JAMA Oncology.

Osimertinib plus chemotherapy conferred significantly greater improvement in PFS compared with osimertinib alone in patients with EGFR-mutated advanced non-small cell lung cancer, according to study results.

The addition of benmelstobart and anlotinib to chemotherapy significantly improved median PFS and OS compared with chemotherapy alone among patients with extensive-stage small cell lung cancer, according to study results.

With the exception of sigmoidoscopy, common cancer screening tests do not appear to extend patients’ lifetimes, according to the results of research published in JAMA Internal Medicine.

Prescription medications added onto tobacco longitudinal care did not improve long-term abstinence rates among current smokers eligible for lung cancer screening, according to results published in JAMA Network Open.

Amivantamab-vmjw — with or without the addition of lazertinib — improved PFS versus chemotherapy alone in patients with EGFR-mutated non-small cell lung cancer, according to the agent’s manufacturer.

Adjuvant therapy with alectinib prolonged DFS compared with platinum-based chemotherapy for certain patients with lung cancer, according to the agent’s manufacturer.

Assessment of body composition measurements on lung screening low-dose CT scans revealed patients at high risk for mortality due to lung cancer, cardiovascular disease and all causes, according to results published in Radiology.

In the ONCO-DVT trial, patients with cancer and isolated distal deep vein thrombosis had fewer thrombotic events at 1 year with 12-month vs. 3-month edoxaban therapy, a finding that could change clinical guidance, according to a speaker.

Researchers have developed a method to predict which individuals are at higher risk for lung cancer-related mortality.